Trial Profile
A study of GX-I7 in patients with glioblastoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 30 May 2018
Price :
$35
*
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 25 May 2018 According to a Genexine media release, the US FDA has cleared Investigative New Drug (IND) application for GX-17 facilitating this trial.
- 29 Dec 2017 New trial record
- 25 Dec 2017 According to an I-Mab Biopharma media release, the company has planned this trial for 2018.